Toshiyuki Tahara

Pemafibrate decreases markers of hepatic inflammation in patients with non-alcoholic fatty liver disease

Satoshi Shinozaki, Toshiyuki Tahara, Alan Kawarai Lefor et al. · Clinical and Experimental Hepatology · 2020 · 48 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Clinical significance of microsatellite instability in the inflamed mucosa for the prediction of colonic neoplasms in patients with ulcerative colitis

Toshiyuki Tahara, Nagamu Inoue, Tadakazu Hisamatsu et al. · Journal of Gastroenterology and Hepatology · 2005 · 45 citations

Medicine, Oncology, Pathology +17

Medium‐chain triglycerides supplement therapy with a low‐carbohydrate formula can supply energy and enhance ammonia detoxification in the hepatocytes of patients with adult–onset type II citrullinemia

Kiyoshi Hayasaka, Chikahiko Numakura, Mitsunori Yamakawa et al. · Journal of Inherited Metabolic Disease · 2018 · 43 citations

Life Sciences, Nutrition, Nutritional Sciences +16

Pemafibrate improves hepatic inflammation,function and fibrosis in patients with non-alcoholicfatty liver disease: a one-year observational study

Satoshi Shinozaki, Toshiyuki Tahara, Alan Kawarai Lefor et al. · Clinical and Experimental Hepatology · 2021 · 36 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +16

Real‐world efficacy and safety of 12‐week sofosbuvir/velpatasvir treatment for patients with decompensated liver cirrhosis caused by hepatitis C virus infection

Yoshinari Takaoka, Kouichi Miura, Naoki Morimoto et al. · Hepatology Research · 2020 · 25 citations

Pharmacy, Infectious Diseases, Pharmacotherapy +17